

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION FOR THE PAPERLESS LISTING REGIME AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited in relation to the proposed amendments to the existing memorandum and articles of association of the Company (the “**Existing Memorandum and Articles of Association**”) to align with the latest regulatory requirements regarding the expanded paperless listing regime and the electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Listing Rules which took effect from 31 December 2023 (the “**Paperless Listing Regime**”).

References are made to the announcement of the Company dated 28 March 2024 and the circular of the Company dated 7 May 2024 in relation to, among other things, the extraordinary general meeting of the Company held on 31 May 2024 (“**Previous EGM**”) at which, among others, a special resolution (the “**Special Resolution**”) was proposed to approve the proposed amendments to the Existing Memorandum and Articles of Association to comply with the Paperless Listing Regime and adopt the second amended and restated memorandum and articles of association of the Company. However, as disclosed in the poll results announcement of the Company dated 31 May 2024, the Special Resolution was not passed and therefore, the second amended and restated memorandum and articles of association of the Company was not adopted.

In order of the above and to align with the Paperless Listing Regime and incorporate certain housekeeping amendments, the board (the “**Board**”) of directors (the “**Directors**”) of the Company proposes again to make the proposed amendments to the Existing Memorandum and Articles of Association (the “**Proposed Amendments**”) and adopt the second amended and restated memorandum and articles of association of the Company (the “**New Memorandum and Articles of Association**”) which consolidates the Proposed Amendments in substitution for, and to the exclusion of, the Existing Memorandum and Articles of Association in their entirety.

The Proposed Amendments and the adoption of the New Memorandum and Articles of Association are subject to the approval of the shareholders of the Company by way of a special resolution at the extraordinary general meeting of the Company (the “EGM”) to be convened and held by the Company. A circular containing, inter alia, details of the Proposed Amendments and the adoption of the New Memorandum and Articles of Association, together with a notice convening the EGM, will be despatched to the shareholders of the Company in due course.

By Order of the Board
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 23 October 2024

As at the date of this announcement, the Board comprises Mr. An Meng and Professor Zhu Quan as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Ms. Chen Yujun and Professor Li Yikai as independent non-executive Directors.